Hetero Research Foundation

Hetero Drugs Limited

Other

Dasari Muralidhara Reddy

Bandi Parthasaradhi Reddy

Kura Rathnakar Reddy

Rapolu Raji Reddy

Bandi Vamsi Krishna

Kesireddy Subash Chander Reddy

Thungathurthy Srinivasa Rao

Adulla Venkat Narsimha Reddy

Jambula Mukunda Reddy

Nagabelli Murali

Thungathurthy Srinivas Rao

Raji Reddy

Matta Ramakrishna Reddy

Dandamudi Satish Kumar

Voggu Ramesh Reddy

Mogili Narsingam

Ayyalasomayajula Satya Srinivas

Medabalimi Peter Paul Raj

Katham Srinivasa Reddy

Puchakayala Srinivasa Reddy

Itiyala Srinivas Reddy

Attunuri Narasa Reddy

Rapolu Raju Reddy

Matta Ramakrishna Krishna Reddy

Maruthi Janakiram Reddy

Samala Malla Reddy

Valivarthi Vsv Prasad

Bandi Vamsi Krishan

Kura Rathnakarreddy

Ayyalsomayajula Satya Srinivas

The present invention provides a novel process for the preparation of pomalidomide crystalline Form I. The present invention also provides a process for the purification of pomalidomide.

Process for pomalidomide

The present invention provides a solid dispersion of rufinamide in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.

Rufinamide solid dispersion

The present invention provides a novel processes for preparation of methyl 3-(benzyloxy)-5-(2,4-difluorobenzylcarbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyiridine-2-carboxylate using novel intermediates.

Process for the preparation of intermediate of dolutegravir

The present invention provides an improved process for the preparation of 4&#x3b1;-acetoxy-2&#x3b1;-benzoyloxy-5&#x3b2;,20-epoxy-1&#x3b2;,13&#x3b1;-dihydroxy-7&#x3b2;,10&#x3b2;-dimethoxy-9-oxo-11-taxene (7&#x3b2;,10&#x3b2;-dimethoxy-10-deacetoxybaccatin III). The present invention also provides a novel process for the preparation of cabazitaxel.

Process for cabazitaxel

The present invention provides a novel process for the purification of alpha-propargylhomoterephthalic acid dimethyl ester substantially free of homoterephthalic acid dimethyl ester. The present invention also provides a novel process for the purification of pralatrexate.

Process for pralatrexate

Described herein is pure amorphous darunavir, methods of making pure amorphous darunavir and pharmaceutical compositions containing amorphous darunavir and a pharmaceutically acceptable excipient.

Amorphous darunavir

The present invention provides a novel amorphous Form of azilsartan acid, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides novel crystalline Forms of azilsartan medoxomil, processes for their preparations and pharmaceutical compositions comprising them. The present invention further provides a novel amorphous Form of azilsartan medoxomil potassium, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides a novel process for the preparation of azilsartan medoxomil potassium crystalline Form II.

Polymorphs of azilsartan medoxomil

The present invention provides novel polymorphs of Lomitapide, process for their preparation and pharmaceutical compositions comprising them. The present invention also provides a novel polymorph of Lomitapide mesylate, process for its preparation and pharmaceutical compositions comprising it.

Polymorphs of lomitapide and its salts

The present invention provides novel solvated forms of darunavir and processes for their preparation. The present invention also provides novel processes for the preparation of darunavir amorphous form and pharmaceutical compositions comprising it. Thus, for example, darunavir 2-methyl-2-butanol solvate was dissolved in methylene dichloride, distilled under vacuum at 45&#xb0; C. to obtain a residue, cyclohexane was added to the residue and stirred for 30 hours at 20 to 25&#xb0; C., and the separated solid was filtered, washed with cyclohexane and dried under vacuum at 50&#xb0; C. for 12 hours to yield darunavir amorphous form.

Polymorphs of darunavir

The present invention provides a novel process for reducing palladium content in fosaprepitant dimeglumine.

Process for fosaprepitant

The present invention provides processes for the preparation of i) Regorafenib (4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, BAY 73-4506, Stivarga&#xae;) and its pharmaceutically acceptable salt thereof; ii) a crystalline solid of Regorafenib tosylate; iii) Regorafenib Polymorph I from Regorafenib tosylate, and iv) a pure 4-(4-amino-3-fluorophenoxy)-N-methylpicolinamide from 4-amino-3-fluorophenol and 4-chloro-N-methylpicolinamide in the presence of potassium tert-butoxide.

Process for Regorafenib

The present invention provides a novel amorphous solid dispersion of linagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.

Linagliptin solid dispersion

The present invention provides a process for the preparation of 1H-benzimidazol-1-methyl-5-N,N-di(2-hydroxyethyl)-2-butanoic acid ethyl ester. The present invention also provides a process for the preparation of bendamustine hydrochloride. The present invention further provides a process for the purification of bendamustine hydrochloride.

Process for bendamustine hydrochloride

The present invention provides a novel process for the preparation of rilpivirine. The present invention also provides a novel process for the preparation of rilpivirine hydrochloride. The present invention further provides a rilpivirine hydrochloride monohydrate, process for its preparation and pharmaceutical compositions comprising it.

Rilpivirine hydrochloride

The present invention provides novel crystalline hydrochloride salt of darunavir, process for its preparation and to pharmaceutical composition comprising it. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it.

Growing community of inventors

Hyderabad Telangana, India

Dasari Muralidhara Reddy